Assumption of Losses Associated with Launching the Laser Eyewear Business
First written in FY2021-Q3. 13 of 22 entries say "Mitigated", first in FY2021. Latest entry: 2026-08-10.
No other company in this theme has enough history to compare yet.
- 2026-08-10MitigatedFinancial results briefing materials
「In the LS Business, the operating loss improved due to higher sales, and company-wide operating loss improved by ¥45 million, or 50%, year on year to ¥45 million.」
The operating loss of the Laser and Optical Solutions Business improved from the same period of the previous year. - FY2026MitigatedAnnual report
「As a result, net sales for the fiscal year were ¥199.552 million, up 6.1% from the previous fiscal year, and segment loss was ¥135.781 million (segment loss of ¥311.751 million in the previous fiscal year).」
Losses in the laser and optical solutions business continued, but segment loss narrowed from ¥311.751 million to ¥135.781 million as net sales increased. - FY2026-H1MitigatedAnnual report
「As a result, net sales for the six months ended the interim period were ¥52.465 million, up 43.2% year on year, and segment loss was ¥100.410 million (segment loss of ¥223.289 million in the same period of the previous year).」
Losses in the visual information devices business continued, but segment loss narrowed from the same period of the previous year as net sales increased. - FY2025MitigatedAnnual report
「As a result, net sales for the fiscal year were ¥188.151 million, down 39.9% from the previous fiscal year, and segment loss was ¥311.751 million (segment loss of ¥375.604 million in the previous fiscal year).」
The visual information devices business recorded lower net sales, but segment loss narrowed from ¥375.604 million to ¥311.751 million. - FY2025-H1WorsenedAnnual report
「As a result, net sales for the six months ended the interim period were ¥36.648 million, down 80.4% year on year, and segment loss was ¥223.289 million (segment loss of ¥146.932 million in the same period of the previous year).」
The visual information devices business recorded a substantial decline in net sales, while segment loss increased from ¥146.932 million in the same period of the previous year to ¥223.289 million. - FY2024WorsenedAnnual report
「As a result, net sales for the fiscal year were ¥312.816 million, up 16.7% from the previous fiscal year, and segment loss was ¥375.604 million (¥338.408 million in the previous fiscal year), due mainly to increased inventory valuation losses, centered on RETISSA ON HAND.」
The laser eyewear business recorded higher net sales, but segment loss increased from ¥338.408 million to ¥375.604 million due mainly to increased inventory valuation losses, centered on ON HAND. - FY2024-Q3MitigatedAnnual report
「During the nine months ended December 31, sales increased from the previous year because of North American sales of RETISSA NEOVIEWER, a retinal-projection viewfinder, and higher sales of RETISSA MEOCHECK, an eye-health check tool, and eye-health check services. As a result, nine-month sales were ¥235,220 thousand, up 211.0% year on year, and the segment loss was ¥217,182 thousand, compared with a segment loss of ¥268,447 thousand in the same period of the previous year.」
Losses in the laser eyewear business continued, but net sales increased through North American sales and higher sales of MEOCHECK and the eye health check service, narrowing segment loss from ¥268.447 million in the same period of the previous year to ¥217.182 million. - FY2024-Q2MitigatedAnnual report
「During the six months ended the second quarter, net sales increased from the same period of the previous year, driven by North American sales of the retinal projection viewfinder RETISSA NEOVIEWER, increased sales of the eye health check tool RETISSA MEOCHECK and increased sales of the eye health check service, among other factors. As a result, net sales for the six months ended the second quarter were ¥186.529 million, up 386.9% year on year, and segment loss was ¥146.932 million (segment loss of ¥184.551 million in the same period of the previous year).」
Losses in the laser eyewear business continued, but net sales increased substantially through North American sales and higher sales of MEOCHECK and the eye health check service, narrowing segment loss from the same period of the previous year. - FY2024-Q1MitigatedAnnual report
「Sales increased following the launch of sales in North America of the retinal-projection viewfinder RETISSA NEOVIEWER. As a result, first-quarter sales were ¥45,972 thousand, up 161.1% year on year, and the segment loss was ¥67,795 thousand, compared with a segment loss of ¥81,457 thousand in the same period of the previous year.」
Losses from launching the laser eyewear business continued, but net sales increased with the start of sales in North America and other factors, narrowing segment loss from the same period of the previous year. - FY2023MitigatedAnnual report
「As a result, net sales for the fiscal year were ¥268.127 million, up 182.7% from the previous fiscal year, and segment loss was ¥338.408 million, reduced by the increase in net sales (¥693.462 million in the previous fiscal year).」
Losses in the laser eyewear business continued, but segment loss narrowed from ¥693.462 million in the previous fiscal year to ¥338.408 million as net sales increased. - FY2023-Q3WorsenedAnnual report
「As a result, net sales for the nine months ended the third quarter were ¥75.640 million, up 96.1% year on year, and segment loss was ¥268.447 million (segment loss of ¥194.391 million in the same period of the previous year).」
The laser eyewear business recorded higher net sales, but segment loss increased from the same period of the previous year, worsening the launch-related loss burden. - FY2023-Q2WorsenedAnnual report
「As a result, net sales for the six months ended the second quarter were ¥38.306 million, up 13.4% year on year, and segment loss was ¥184.551 million (segment loss of ¥138.349 million in the same period of the previous year).」
The laser eyewear business recorded higher net sales, but segment loss increased from ¥138.349 million in the same period of the previous year to ¥184.551 million. - FY2023-Q1WorsenedAnnual report
「As a result, net sales for the three months ended the first quarter were ¥17.608 million, up 6.8% year on year, and segment loss was ¥81.457 million (segment loss of ¥73.922 million in the same period of the previous year).」
The laser eyewear business recorded higher net sales, but segment loss increased from ¥73.922 million in the same period of the previous year to ¥81.457 million, worsening the launch-related loss burden. - FY2022WorsenedAnnual report
「The company recorded an inventory valuation loss of ¥408.695 million in the laser eyewear business. Operating loss was ¥931.547 million (¥654.825 million in the previous fiscal year), and ordinary loss was ¥893.536 million (¥707.769 million).」
Inventory valuation losses in the laser eyewear business caused operating and ordinary losses to increase from the previous fiscal year. - FY2022-Q3MitigatedAnnual report
「During the nine months ended the third quarter, orders for consumer retinal-scanning laser eyewear increased, driven by sales to financial institution branches and the launch of accessory camera sales. As a result, net sales for the nine months ended the third quarter were ¥38.579 million, up 14.4% year on year, and segment loss was ¥194.391 million (segment loss of ¥309.534 million in the same period of the previous year).」
Losses in the laser eyewear business continued, but net sales increased and segment loss narrowed by ¥115.143 million from the same period of the previous year. - FY2022-Q2MitigatedAnnual report
「During the six months ended the second quarter, orders for consumer retinal-scanning laser eyewear increased, driven by sales to financial institution branches and the launch of accessory camera sales. As a result, net sales for the six months ended the second quarter were ¥33.770 million, up 131.4% year on year, and segment loss was ¥138.349 million (segment loss of ¥226.797 million in the same period of the previous year).」
Launch-related losses in the laser eyewear business continued, but net sales increased and segment loss narrowed from the same period of the previous year. - FY2022-Q1RestatedAnnual report
「As the laser eyewear business is still being launched, selling, general and administrative expenses continued to exceed net sales. Operating loss was ¥200.691 million, ordinary loss was ¥202.745 million and net loss for the quarter was ¥206.244 million.」
Selling, general and administrative expenses exceeded net sales during the launch phase of the laser eyewear business, and losses continued. - FY2021MitigatedAnnual report
「As the laser eyewear business is still being launched, the fixed-cost burden, mainly development expenses, remains substantial. Operating loss was ¥654.825 million (¥1,207.239 million in the previous fiscal year), ordinary loss was ¥707.769 million (¥1,225.739 million) and net loss for the period was ¥879.829 million (¥1,240.167 million).」
Launch-related losses continued, but operating, ordinary and net losses all narrowed from the previous fiscal year. - FY2021-Q3First statedAnnual report
「As the laser eyewear business is still being launched, the fixed-cost burden, mainly development expenses, remains substantial. Operating loss was ¥493.676 million, ordinary loss was ¥537.249 million and net loss for the quarter was ¥699.671 million.」
The disclosure records the fixed-cost burden from development expenses and other costs during the launch phase, together with operating, ordinary and net losses.